Lisa Devereux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8347053/publications.pdf Version: 2024-02-01



LISA DEVEDELLY

#	Article	IF	CITATIONS
1	Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. Journal of Clinical Oncology, 2016, 34, 1455-1459.	1.6	154
2	Identification of a new family of human epithelial protein kinases containing two leucine/isoleucine-zipper domains. FEBS Journal, 1993, 213, 701-710.	0.2	107
3	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66
4	Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. Genetics in Medicine, 2019, 21, 913-922.	2.4	45
5	Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Research, 2015, 17, 111.	5.0	36
6	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021, 12, 5049.	12.8	33
7	Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context. Scientific Reports, 2015, 5, 14800.	3.3	26
8	Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 1332-1338.	6.3	26
9	Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs. Breast Cancer Research, 2018, 20, 3.	5.0	19
10	Mutations in RECQL are not associated with breast cancer risk in an Australian population. Nature Genetics, 2018, 50, 1346-1348.	21.4	19
11	Reevaluation of RINT1 as a breast cancer predisposition gene. Breast Cancer Research and Treatment, 2016, 159, 385-392.	2.5	16
12	Molecular comparison of interval and screenâ€detected breast cancers. Journal of Pathology, 2019, 248, 243-252.	4.5	15
13	Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study. Npj Breast Cancer, 2021, 7, 76.	5.2	12
14	A Review of International Biobanks and Networks: Success Factors and Key Benchmarks—A 10-Year Retrospective Review. Biopreservation and Biobanking, 2019, 17, 512-519.	1.0	10
15	Exploring Implementation of Personal Breast Cancer Risk Assessments. Journal of Personalized Medicine, 2021, 11, 992.	2.5	9
16	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. Npj Breast Cancer, 2021, 7, 52.	5.2	7
17	The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. Npj Breast Cancer, 2020, 6, 34.	5.2	4
18	The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study. Journal of Personalized Medicine, 2022, 12, 1112.	2.5	2

#	Article	IF	CITATIONS
19	Biobanking in Cancer Research. , 2016, , 27-49.		1
20	Contribution of large genomic rearrangements in <i>PALB2</i> to familial breast cancer: implications for genetic testing. Journal of Medical Genetics, 2023, 60, 112-118.	3.2	1
21	Unselected Women's Experiences of Receiving Genetic Research Results for Hereditary Breast and Ovarian Cancer: A Qualitative Study. Genetic Testing and Molecular Biomarkers, 2021, 25, 741-748.	0.7	1
22	Mixed Lineage Kinases. , 1995, , 369-380.		0
23	Integration of tumour sequencing and case–control data to assess pathogenicity of RAD51C missense variants in familial breast cancer. Npj Breast Cancer, 2022, 8, 10.	5.2	0